SCHEDULE: Processa Pharmaceuticals Stakeholder Filing

CVI Investments, Inc. and Heights Capital Management, Inc. report a combined 7.0% beneficial ownership of Processa Pharmaceuticals, Inc. common stock.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. have jointly filed a Schedule 13G, indicating their beneficial ownership of Processa Pharmaceuticals, Inc. common stock.
• The filing reports a total of 200,000 shares beneficially owned, representing 7.0% of the class.
• Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc. and may exercise voting and dispositive power over these shares.
• The reported shares are issuable upon the exercise of warrants.
• As of March 31, 2026, Processa Pharmaceuticals, Inc. had 2,677,835 shares outstanding.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of beneficial ownership and does not provide operational or financial performance data for the company itself.

Positives

• Significant stake reported by investment entities, potentially indicating confidence or strategic interest in Processa Pharmaceuticals.
• Clear disclosure of beneficial ownership, adhering to regulatory requirements.

Negatives

• The filing does not provide financial performance data or operational updates for Processa Pharmaceuticals, Inc.

Risks

• The beneficial ownership is tied to the exercise of warrants, meaning the actual ownership is contingent on these warrants being exercised.
• Potential for future changes in ownership stake as warrants are exercised or disposed of.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Processa Pharmaceuticals, Inc.'s future performance. It solely reports on beneficial ownership.

Management Comments

• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.
• Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment managers accumulating significant stakes in publicly traded companies. This filing indicates a notable position held by CVI Investments, Inc. and managed by Heights Capital Management, Inc. in Processa Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders: May be interested in the significant stake held by CVI Investments and Heights Capital Management, potentially influencing market perception or future corporate actions.
• Creditors: The filing does not directly impact creditors as it does not concern the company's financial health or debt.
• Employees: No direct impact mentioned in the filing.
• Suppliers: No direct impact mentioned in the filing.
• Customers: No direct impact mentioned in the filing.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership stake in Processa Pharmaceuticals, Inc.
• Processa Pharmaceuticals, Inc. will continue its business operations, the details of which are not covered in this filing.

Key Dates

Keywords

Schedule 13G, Processa Pharmaceuticals, CVI Investments, Heights Capital Management, Beneficial Ownership, Warrants, SEC Filing, Securities Exchange Act